MoonLake Immunotherapeutics
MLTX
$17.80
-$0.20-1.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -257.08M | -227.32M | -210.50M | -176.16M | -145.21M |
| Total Depreciation and Amortization | 3.08M | 2.62M | 2.23M | 1.84M | 1.44M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.81M | 8.82M | 6.61M | 5.08M | 5.30M |
| Change in Net Operating Assets | 9.04M | 19.88M | 15.97M | 2.82M | -1.31M |
| Cash from Operations | -224.15M | -196.01M | -185.69M | -166.42M | -139.78M |
| Capital Expenditure | 0.00 | -35.00K | -211.00K | -343.00K | -343.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 146.84M | 203.03M | 85.78M | 55.79M | -120.20M |
| Cash from Investing | 146.84M | 202.99M | 85.57M | 55.45M | -120.55M |
| Total Debt Issued | 24.47M | 73.02M | 73.02M | 73.02M | 73.02M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 79.05M | 72.98M | 731.00K | 342.00K | 342.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 92.00K | 92.00K |
| Cash from Financing | 103.52M | 146.00M | 73.75M | 73.46M | 73.46M |
| Foreign Exchange rate Adjustments | 714.00K | 1.11M | 1.44M | 1.40M | -6.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 26.92M | 154.09M | -24.92M | -36.11M | -186.88M |